105 related articles for article (PubMed ID: 32641738)
1. The deleterious association between proton pump inhibitors and prostate cancer-specific mortality - a population-based cohort study.
Goldberg H; Mohsin FK; Saskin R; Kulkarni GS; Berlin A; Kenk M; Wallis CJD; Chandrasekar T; Klaassen Z; Saarela O; Penn L; Alibhai SMH; Fleshner N
Prostate Cancer Prostatic Dis; 2020 Dec; 23(4):622-629. PubMed ID: 32641738
[TBL] [Abstract][Full Text] [Related]
2. Use of proton pump inhibitors and mortality among Icelandic patients with prostate cancer.
Hálfdánarson ÓÖ; Pottegård A; Lund SH; Ogmundsdottir MH; Ogmundsdottir HM; Zoega H
Basic Clin Pharmacol Toxicol; 2020 Jun; 126(6):484-491. PubMed ID: 31872571
[TBL] [Abstract][Full Text] [Related]
3. The Suggested Unique Association Between the Various Statin Subgroups and Prostate Cancer.
Goldberg H; Mohsin FK; Saskin R; Kulkarni GS; Berlin A; Kenk M; Wallis CJD; Klaassen Z; Chandrasekar T; Ahmad AE; Sayyid RK; Saarela O; Penn L; Alibhai SMH; Fleshner N
Eur Urol Focus; 2021 May; 7(3):537-545. PubMed ID: 32620539
[TBL] [Abstract][Full Text] [Related]
4. The risk of prostate cancer mortality and cardiovascular mortality of nonmetastatic prostate cancer patients: A population-based retrospective cohort study.
Matthes KL; Pestoni G; Korol D; Van Hemelrijck M; Rohrmann S
Urol Oncol; 2018 Jun; 36(6):309.e15-309.e23. PubMed ID: 29576269
[TBL] [Abstract][Full Text] [Related]
5. Posttreatment Prostate-Specific Antigen 6 Months After Radiation With Androgen Deprivation Therapy Predicts for Distant Metastasis-Free Survival and Prostate Cancer-Specific Mortality.
Naik M; Reddy CA; Stephans KL; Ciezki JP; Garcia J; Grivas P; Stephenson AJ; Klein EA; Tendulkar RD
Int J Radiat Oncol Biol Phys; 2016 Nov; 96(3):617-23. PubMed ID: 27681757
[TBL] [Abstract][Full Text] [Related]
6. Prostate cancer survival among statin users after prostatectomy in a Finnish nationwide cohort.
Joentausta RM; Rannikko A; Murtola TJ
Prostate; 2019 May; 79(6):583-591. PubMed ID: 30652328
[TBL] [Abstract][Full Text] [Related]
7. Associations between statin use and progression in men with prostate cancer treated with primary androgen deprivation therapy.
Mikkelsen MK; Thomsen FB; Berg KD; Jarden M; Larsen SB; Hansen RB; Brasso K
Scand J Urol; 2017 Dec; 51(6):464-469. PubMed ID: 28831860
[TBL] [Abstract][Full Text] [Related]
8. Use of β-blockers is associated with prostate cancer-specific survival in prostate cancer patients on androgen deprivation therapy.
Grytli HH; Fagerland MW; Fosså SD; Taskén KA; Håheim LL
Prostate; 2013 Feb; 73(3):250-60. PubMed ID: 22821802
[TBL] [Abstract][Full Text] [Related]
9. Ten-year survival after High-Dose-Rate Brachytherapy combined with External Beam Radiation Therapy in high-risk prostate cancer: A comparison with the Norwegian SPCG-7 cohort.
Wedde TB; Småstuen MC; Brabrand S; Fosså SD; Kaasa S; Tafjord G; Russnes KM; Hellebust TP; Lilleby W
Radiother Oncol; 2019 Mar; 132():211-217. PubMed ID: 30389241
[TBL] [Abstract][Full Text] [Related]
10. The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy.
Dong Y; Ruth KJ; Churilla TM; Viterbo R; Sobczak ML; Smaldone MC; Chen DY; Uzzo RG; Hallman MH; Horwitz EM
Can J Urol; 2017 Feb; 24(1):8656-8662. PubMed ID: 28263132
[TBL] [Abstract][Full Text] [Related]
11. Differences in time to disease progression do not predict for cancer-specific survival in patients receiving immediate or deferred androgen-deprivation therapy for prostate cancer: final results of EORTC randomized trial 30891 with 12 years of follow-up.
Studer UE; Whelan P; Wimpissinger F; Casselman J; de Reijke TM; Knönagel H; Loidl W; Isorna S; Sundaram SK; Collette L;
Eur Urol; 2014 Nov; 66(5):829-38. PubMed ID: 23932338
[TBL] [Abstract][Full Text] [Related]
12. Ten-year outcomes of high-dose intensity-modulated radiation therapy for nonmetastatic prostate cancer with unfavorable risk: early initiation of salvage therapy may replace long-term adjuvant androgen deprivation.
Aizawa R; Takayama K; Nakamura K; Inoue T; Yamasaki T; Kobayashi T; Akamatsu S; Ogawa O; Mizowaki T
Int J Clin Oncol; 2019 Oct; 24(10):1247-1255. PubMed ID: 31152322
[TBL] [Abstract][Full Text] [Related]
13. Large institutional variations in use of androgen deprivation therapy with definitive radiotherapy in a population-based cohort of men with intermediate- and high-risk prostate cancer.
Ong WL; Foroudi F; Evans S; Millar J
BJU Int; 2017 Nov; 120 Suppl 3():35-42. PubMed ID: 28749017
[TBL] [Abstract][Full Text] [Related]
14. Individual prognosis at diagnosis in nonmetastatic prostate cancer: Development and external validation of the PREDICT Prostate multivariable model.
Thurtle DR; Greenberg DC; Lee LS; Huang HH; Pharoah PD; Gnanapragasam VJ
PLoS Med; 2019 Mar; 16(3):e1002758. PubMed ID: 30860997
[TBL] [Abstract][Full Text] [Related]
15. Medical androgen deprivation therapy and increased non-cancer mortality in non-metastatic prostate cancer patients aged ≥66 years.
Abdollah F; Sammon JD; Reznor G; Sood A; Schmid M; Klett DE; Sun M; Aizer AA; Choueiri TK; Hu JC; Kim SP; Kibel AS; Nguyen PL; Menon M; Trinh QD
Eur J Surg Oncol; 2015 Nov; 41(11):1529-39. PubMed ID: 26210655
[TBL] [Abstract][Full Text] [Related]
16. Combined Androgen Blockade in Localized Prostate Cancer Treated With Definitive Radiation Therapy.
Vitzthum LK; Straka C; Sarkar RR; McKay R; Randall JM; Sandhu A; Murphy JD; Rose BS
J Natl Compr Canc Netw; 2019 Dec; 17(12):1497-1504. PubMed ID: 31805534
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the effectiveness of adding androgen deprivation to modern dose-escalated radiotherapy for men with favorable intermediate-risk prostate cancer.
Falchook AD; Basak R; Mohiuddin JJ; Chen RC
Cancer; 2016 Aug; 122(15):2341-9. PubMed ID: 27191936
[TBL] [Abstract][Full Text] [Related]
18. Short-course androgen deprivation therapy and the risk of death from high-risk prostate cancer in men undergoing external beam radiation therapy and brachytherapy.
Raldow AC; Zhang D; Chen MH; Braccioforte MH; Moran BJ; D'Amico AV
Brachytherapy; 2015; 14(6):781-7. PubMed ID: 26361718
[TBL] [Abstract][Full Text] [Related]
19. Patients with prostate cancer and androgen deprivation therapy have increased risk of fractures-a study from the fractures and fall injuries in the elderly cohort (FRAILCO).
Wallander M; Axelsson KF; Lundh D; Lorentzon M
Osteoporos Int; 2019 Jan; 30(1):115-125. PubMed ID: 30324413
[TBL] [Abstract][Full Text] [Related]
20. Early Versus Delayed Initiation of Salvage Androgen Deprivation Therapy and Risk of Prostate Cancer-Specific Mortality.
Mahal BA; Chen MH; Renshaw AA; Loffredo MJ; Kantoff PW; D'Amico AV
J Natl Compr Canc Netw; 2018 Jun; 16(6):727-734. PubMed ID: 29891524
[No Abstract] [Full Text] [Related]
[Next] [New Search]
